[go: up one dir, main page]

NO972591L - Steroid reseptormodulator-forbindelser og fremgangsmåter - Google Patents

Steroid reseptormodulator-forbindelser og fremgangsmåter

Info

Publication number
NO972591L
NO972591L NO972591A NO972591A NO972591L NO 972591 L NO972591 L NO 972591L NO 972591 A NO972591 A NO 972591A NO 972591 A NO972591 A NO 972591A NO 972591 L NO972591 L NO 972591L
Authority
NO
Norway
Prior art keywords
compounds
steroid receptor
methods
receptor modulator
disclosed
Prior art date
Application number
NO972591A
Other languages
English (en)
Other versions
NO972591D0 (no
NO310617B1 (no
Inventor
Todd K Jones
Mark E Goldman
Charlotte L F Pooley
David T Winn
James E Edwards
Sarah J West
Christopher M Tegley
Lin Zhi
Lawrence G Hamann
Luc J Farmer
Robert J Davis
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/462,643 external-priority patent/US5696130A/en
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of NO972591D0 publication Critical patent/NO972591D0/no
Publication of NO972591L publication Critical patent/NO972591L/no
Publication of NO310617B1 publication Critical patent/NO310617B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ikke-steroide forbindelser som er hay-affinitets, høy-selektivmodulatorer for steroidreseptorer. Det blir også beskrevet farmasøytiske sammensetninger som inkorporerer slike forbindelser, fremgangsmåter for å benytte de beskrevne forbindelsene og sammensetninger for å behandle pasienter som krever steroidreseptor-agonist- eller -antagonistterapi, mellomprodukter som er nyttige i fremstillingen av forbindelsene og fremgangsmåter for fremstilling av steroidreseptor-modulatorforbindelsene.
NO19972591A 1994-12-22 1997-06-06 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse, samt anvendelse avforbindelsene eller sammensetningene for fremstilling avmedikamenter NO310617B1 (no)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US36352994A 1994-12-22 1994-12-22
US08/462,643 US5696130A (en) 1994-12-22 1995-06-05 Tricyclic steroid receptor modulator compounds and methods
US08/463,231 US5688808A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/464,541 US5688810A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/464,360 US5693646A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/465,429 US5696127A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/464,546 US5693647A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/465,556 US5696133A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
PCT/US1995/016096 WO1996019458A2 (en) 1994-12-22 1995-12-13 Steroid receptor modulator compounds and methods

Publications (3)

Publication Number Publication Date
NO972591D0 NO972591D0 (no) 1997-06-06
NO972591L true NO972591L (no) 1997-08-14
NO310617B1 NO310617B1 (no) 2001-07-30

Family

ID=27575415

Family Applications (5)

Application Number Title Priority Date Filing Date
NO19972591A NO310617B1 (no) 1994-12-22 1997-06-06 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse, samt anvendelse avforbindelsene eller sammensetningene for fremstilling avmedikamenter
NO20003534A NO312162B1 (no) 1994-12-22 2000-07-07 Progesteronreseptor-modulatorforbindelser, farmasöytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
NO20003552A NO313049B1 (no) 1994-12-22 2000-07-10 Progesteron-agonistforbindelser, farmasöytiske preparater inneholdende disse og anvendelsen av forbindelsen
NO20003551A NO312098B1 (no) 1994-12-22 2000-07-10 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse samt anvendelse avforbindelsene
NO20003550A NO20003550D0 (no) 1994-12-22 2000-07-10 Farmasøytiske sammensetninger og anvendelse herav

Family Applications After (4)

Application Number Title Priority Date Filing Date
NO20003534A NO312162B1 (no) 1994-12-22 2000-07-07 Progesteronreseptor-modulatorforbindelser, farmasöytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
NO20003552A NO313049B1 (no) 1994-12-22 2000-07-10 Progesteron-agonistforbindelser, farmasöytiske preparater inneholdende disse og anvendelsen av forbindelsen
NO20003551A NO312098B1 (no) 1994-12-22 2000-07-10 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse samt anvendelse avforbindelsene
NO20003550A NO20003550D0 (no) 1994-12-22 2000-07-10 Farmasøytiske sammensetninger og anvendelse herav

Country Status (17)

Country Link
EP (7) EP1043315A1 (no)
JP (2) JPH10510840A (no)
CN (2) CN1626534A (no)
AT (2) ATE252560T1 (no)
AU (1) AU717251B2 (no)
BR (1) BR9510486A (no)
CA (1) CA2208347A1 (no)
CZ (1) CZ176197A3 (no)
DE (2) DE69533180T2 (no)
DK (1) DK0800519T3 (no)
ES (1) ES2208699T3 (no)
HU (1) HUT78117A (no)
NO (5) NO310617B1 (no)
NZ (1) NZ300739A (no)
PT (1) PT800519E (no)
RU (1) RU2191774C2 (no)
WO (1) WO1996019458A2 (no)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
DE69709752T2 (de) * 1996-06-27 2002-07-18 Ligand Pharmaceuticals, Inc. Androgen rezeptor modulator verbindungen und verfahren
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
AU5729098A (en) * 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US6291442B1 (en) 1998-02-03 2001-09-18 The General Hospital Corporation Pharmacological modulators of voltage-gated potassium ion channels
EP1053239B1 (en) * 1998-02-13 2003-01-08 Abbott Laboratories Glucocorticoid-selective anti-inflammatory agents
US6380207B2 (en) * 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6001846A (en) * 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
US6093825A (en) * 1998-05-27 2000-07-25 American Home Products Methods for preparation of 1,2-dihydroquinolines
US6093826A (en) 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
EP1093362A1 (en) 1998-06-12 2001-04-25 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
WO2000066560A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
AU4501800A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
KR100732692B1 (ko) * 1999-05-04 2007-06-27 와이어쓰 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
CN1145618C (zh) * 1999-05-04 2004-04-14 美国家庭用品有限公司 作为黄体酮受体调节剂的环氨基甲酸酯衍生物
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
KR20020038741A (ko) 1999-08-27 2002-05-23 윌리암 엘. 레스페스 안드로겐 수용체 조절 화합물 및 방법
RO122179B1 (ro) * 1999-08-31 2009-02-27 Schering Aktiengesellschaft Utilizarea de mezoprogestine pentru tratamentul şi prevenirea afecţiunilor ginecologice benigne, hormon-dependente
JP2003529545A (ja) 1999-09-14 2003-10-07 リガンド・ファーマシューティカルズ・インコーポレイテッド 改善された薬理学的プロファイルを有するｒｘｒモジュレーター
AU7558900A (en) * 1999-10-14 2001-04-23 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
MXPA02012605A (es) 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
MXPA02012563A (es) * 2000-06-28 2003-05-14 Squibb Bristol Myers Co Compuestos ciclicos fusionados como moduladores de la funcion del receptor de la hormona nuclear.
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
CA2420289A1 (en) * 2000-08-23 2002-02-28 Akzo Nobel N.V. 10-aryl-11-hbenzo [b]fluorene derivatives and analogs for medicinal use
EP1325914A4 (en) 2000-09-14 2004-11-17 Kaken Pharma Co Ltd TETRAHYDROQUINOLINE COMPOUNDS
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
YU20003A (sh) * 2000-09-19 2006-03-03 Bristol-Myers Squibb Company Spojena heterociklična jedinjenja sukcinamida i njihovi analozi, modulatori funkcije nuklearnog hormonskog receptora
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US6608216B2 (en) 2001-06-29 2003-08-19 Abbott Laboratories Process for the preparation of chiral glucocorticoid receptor agents
WO2003002548A1 (en) * 2001-06-29 2003-01-09 Abbott Laboratories A process for the preparation of chiral glucocorticoid receptor agents
NZ530198A (en) * 2001-07-02 2005-11-25 Akzo Nobel Nv Tetrahydroquinoline derivatives
JP2003073374A (ja) * 2001-08-31 2003-03-12 Kaken Pharmaceut Co Ltd ２環性芳香族アミン誘導体
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
ES2310622T3 (es) 2001-12-19 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
DE60309829T2 (de) 2002-01-14 2007-09-13 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoidmimetika, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische formulierungen und ihre verwendungen
TW200304371A (en) 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
CN1700923B (zh) 2002-02-28 2011-06-15 田纳西大学研究基金会 多取代的选择性雄激素受体调节剂及其使用方法
EP1487792A1 (en) 2002-03-15 2004-12-22 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
MXPA04009329A (es) 2002-03-26 2005-01-25 Boehringer Ingelheim Pharma Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y usos de los mismos.
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003230869B2 (en) * 2002-04-26 2010-02-25 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1532113B1 (en) * 2002-08-21 2008-08-06 Boehringer Ingelheim Pharmaceuticals Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP2298316A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
JP2006504736A (ja) * 2002-10-11 2006-02-09 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的プロゲステロンレセプター調節化合物としての５−（１’，１’−シクロアルキル／アルケニル）メチリデン１，２−ジヒドロ−５Ｈ−クロメノ［３，４−ｆ］キノリン
AU2003258050A1 (en) 2002-10-11 2004-05-04 Ligand Pharmaceuticals Incorporated 5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compounds
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
US7579469B2 (en) 2003-01-03 2009-08-25 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1622872A1 (en) * 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
AU2004266160A1 (en) 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
ATE366726T1 (de) 2003-10-16 2007-08-15 Boehringer Ingelheim Pharma Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
CA2578164A1 (en) * 2004-09-07 2006-03-16 Wyeth 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
US7635711B2 (en) 2004-12-27 2009-12-22 Boehringer-Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
NZ560354A (en) 2005-06-17 2010-10-29 Ligand Pharm Inc Androgen receptor modulator compounds and methods
TWI375676B (en) * 2005-08-29 2012-11-01 Msd Oss Bv Non-steroidal glucocorticoid receptor modulators
CN102304124B (zh) * 2005-09-14 2014-10-22 参天制药株式会社 具有糖皮质激素受体结合活性的1,2-二氢喹啉衍生物
JP4825636B2 (ja) * 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２−ジヒドロキノリン誘導体
US20090203725A1 (en) * 2005-12-21 2009-08-13 Cornelis Arjan Van Oeveren Androgen Receptor Modulator Compounds and Methods
CA2642598C (en) * 2006-03-03 2014-05-27 Orion Corporation Selective androgen receptor modulators
ES2391865T3 (es) 2006-11-14 2012-11-30 Santen Pharmaceutical Co., Ltd Nuevos derivados de 1,2-dihidroquinolina que tienen un grupo fenilamino alquilo inferior y un grupo fenilo introducido por éster como sustituyentes
US8658637B2 (en) 2006-12-06 2014-02-25 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
TWI410422B (zh) * 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
JP2008255112A (ja) * 2007-03-13 2008-10-23 Santen Pharmaceut Co Ltd ２，２，４−トリメチル−６−フェニル−１，２−ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2009103007A2 (en) * 2008-02-13 2009-08-20 Ligand Pharmaceuticals Incorporated Steroid hormone receptor modulator compounds and methods
TWI510240B (zh) * 2008-05-12 2015-12-01 由具有取代氧基之２，２，４－三甲基－６－苯基－１，２－二氫喹啉衍生物組成之糖皮質激素受體激動劑
EP2130831A1 (en) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25 inhibitors
CA2726449A1 (en) 2008-06-06 2009-12-10 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
CN103613538B (zh) * 2013-11-22 2015-05-20 山东斯递尔化工科技有限公司 一种2,2,4-三甲基-1,2-二氢化喹啉聚合体的催化合成工艺
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
JP6768789B2 (ja) 2015-08-13 2020-10-14 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ依存性クッシング症候群を鑑別診断する方法
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用
US10413540B2 (en) 2017-03-31 2019-09-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
CN107805248A (zh) * 2017-11-01 2018-03-16 长春海谱润斯科技有限公司 一种含有苯并咪唑结构的衍生物及其制备方法和有机电致发光器件
CN111499607B (zh) * 2019-01-30 2022-04-19 哈尔滨工业大学（深圳） 一种六元芳基内酯或六元芳基内酰胺化合物的制备方法
JP2022529341A (ja) 2019-04-19 2022-06-21 リガンド・ファーマシューティカルズ・インコーポレイテッド 化合物の結晶形、および化合物の結晶形を生成する方法
CA3205462A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635941A (en) * 1969-04-01 1972-01-18 Eastman Kodak Co Disperse mono azo dyes containing an acylamidotetrahydroquinoline group
GB1379387A (en) * 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
US3907507A (en) * 1971-04-26 1975-09-23 Heliodoro Monroy Rivera Novel apparatus for the obtention of substituted 1,2-dihydroquinolines
GB8619902D0 (en) * 1986-08-15 1986-09-24 Pfizer Ltd Quinolone cardiac stimulants
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8709448D0 (en) * 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
EP1130017B1 (en) * 1990-11-30 2005-06-15 Otsuka Pharmaceutical Co., Ltd. Azole derivatives and their use as superoxide radical inhibitors
JPH04316557A (ja) * 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd ６−アリール環状アントラニル酸誘導体
RU2032685C1 (ru) * 1991-12-16 1995-04-10 Центр по химии лекарственных средств Производные пиридо (3,2-а)карбазола, обладающие кардиотонической активностью
JP2686887B2 (ja) * 1992-08-11 1997-12-08 キッセイ薬品工業株式会社 ピペリジノ−３，４−ジヒドロカルボスチリル誘導体

Also Published As

Publication number Publication date
NZ300739A (en) 2000-05-26
NO20003552L (no) 1997-08-14
NO313049B1 (no) 2002-08-05
NO972591D0 (no) 1997-06-06
RU2191774C2 (ru) 2002-10-27
NO20003551D0 (no) 2000-07-10
JP2007217418A (ja) 2007-08-30
CZ176197A3 (cs) 1998-09-16
NO20003550D0 (no) 2000-07-10
JPH10510840A (ja) 1998-10-20
ATE269336T1 (de) 2004-07-15
DE69531998D1 (de) 2003-11-27
EP1043325B1 (en) 2004-06-16
DE69533180D1 (de) 2004-07-22
NO20003551L (no) 1997-08-14
EP0800519B1 (en) 2003-10-22
EP1382597A2 (en) 2004-01-21
HUT78117A (hu) 1999-11-29
CN1172917C (zh) 2004-10-27
AU4597796A (en) 1996-07-10
BR9510486A (pt) 1998-06-02
NO312098B1 (no) 2002-03-18
NO20003550L (no) 1997-08-14
NO20003552D0 (no) 2000-07-10
WO1996019458A2 (en) 1996-06-27
WO1996019458A3 (en) 1996-12-12
CA2208347A1 (en) 1996-06-27
ATE252560T1 (de) 2003-11-15
EP0800519A1 (en) 1997-10-15
NO312162B1 (no) 2002-04-02
AU717251B2 (en) 2000-03-23
CN1175247A (zh) 1998-03-04
DK0800519T3 (da) 2004-03-01
EP1043326A1 (en) 2000-10-11
EP1041066A1 (en) 2000-10-04
EP1043315A1 (en) 2000-10-11
PT800519E (pt) 2004-03-31
EP1043325A1 (en) 2000-10-11
NO310617B1 (no) 2001-07-30
EP1041071A1 (en) 2000-10-04
ES2208699T3 (es) 2004-06-16
DE69533180T2 (de) 2005-07-14
NO20003534L (no) 1997-08-14
NO20003534D0 (no) 2000-07-07
CN1626534A (zh) 2005-06-15
DE69531998T2 (de) 2004-07-22
EP1382597A3 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
DK0800519T3 (da) Steroidreceptormodulatorforbindelser og fremgangsmåder
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
YU7797A (sh) Kombinovana terapija za osteoporozu
DK0873295T3 (da) Dimer-selektive RXR-modulatorer og fremgangsmåder til deres anvendelse
BG106142A (en) Glucocorticoid receptor modulators
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE245993T1 (de) Allosterische modulatoren des nmda-rezeptors
IT1288388B1 (it) Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
TR199700956T1 (xx) Indazolkarboksamidler.
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
CA2259031A1 (en) Androgen receptor modulator compounds and methods